Does the Number of Harvested Sentinel Lymph Nodes Matter in Breast Cancer Patients with Limited Nodal Burden? A Descriptive Cohort Study.
4 affiliations
- 1Breast Department, KK Women's and Children's Hospital, Singapore 229899, Singapore.
- 2Surgery Academic Clinical Program, Duke-NUS Medical School, National University of Singapore, Singapore 169857, Singapore.
- 3Department of Breast & Gynaecological Radiation Oncology, National Cancer Centre Singapore, Singapore 168583, Singapore.
- 4Centre for Biomedical Data Science, Duke-NUS Medical School, National University of Singapore, Singapore 169857, Singapore.
Abstract
Background/Objectives: In breast cancer patients with limited nodal burden, sentinel lymph node biopsy (SLNB) alone, without axillary lymph node dissection (ALND), has shown non-inferior survival. However, it remains unclear how many SLNs should be harvested. We aimed to determine if the number of harvested SLNs and the use of a single agent for SLNB localisation affect the detection of residual metastatic nodes. We also described the oncological outcome of SLNB alone as an exploratory clinical outcome. Methods: From 1 January 2020 to 31 January 2026, T1-2 patients and 1-2 metastatic SLNs who underwent SLNB only or with completion ALND were analysed. The number of SLNs harvested and the use of single or dual agents for localisation of SLNs were analysed in the ALND group to determine if it affected the detection of residual metastatic nodes. Data on oncological outcomes were reported. Results: A total of 152 patients were enrolled, of which 63 and 89 underwent SLNB alone and ALND respectively. The ALND group had more patients with mastectomy (p = 0.0044), macrometastasis (p = 0.0001) and no radiation to the axilla (p = 0.0001). Median number of harvested SLNs was 3 (range: 1-8) and 2 (range: 1-9) in the SLNB and ALND groups respectively. In the ALND group, a mean residual 2.4 metastatic nodes (range: 1-9) was seen in 24.7%. Multivariable logistic regression showed that a higher SLN yield was not associated with less residual disease (adjusted OR 0.71 per additional SLN, 95% CI [0.46, 1.12]). Conversely, the number of metastatic SLNs was statistically associated with residual nodal disease OR 3.6 95% CI [1.19, 10.86]. Single-agent SLNB localisation (mainly patent blue dye) was used in 22% and 19.3% of SLNB and ALND group respectively. Though dual-agent localisation had more patients with ≥2 SLNs (p = 0.0181), it was not statistically associated with residual nodal metastatic disease which occurred in 7/17 (41.2%) single-agent versus 15/71 (21.1%) dual-agent cases (p = 0.1184; OR 2.58, 95% CI [0.71, 9.09]). No recurrences were observed on a median follow-up of 37 (range: 3-75) months. Conclusions: The number of harvested SLNs and the use of patent blue dye as a single-agent localisation were not statistically associated with residual nodal disease in patients with limited nodal burden. Instead, metastatic SLN burden was statistically significant for residual nodal disease. However, our findings were limited by small sample size and should be considered as exploratory in nature with validation needed in larger studies with longer follow-up.
Related
- Copy-Number Alterations and Copy-Neutral Loss of Heterozygosity in Adult T-ALL: A Descriptive Study in Relation to Day +70 MRD
- Characterising patients in England with Down syndrome and Alzheimer's disease: a descriptive observational study using data from Clinical Practice Research Datalink linked to Hospital Episode Statistics.
- Antiplatelet Therapy Strategies in Patients with High Bleeding Risk Treated with Complex Percutaneous Coronary Intervention: A Descriptive Study
- Out-of-bed mobility during venovenous ECMO among patients listed for lung transplantation: A descriptive single-center cohort study
- Disparities in Tibial Fracture Care for Patients With Limited English Proficiency
BibTeX
@article{lim2026does,
title = {{Does the Number of Harvested Sentinel Lymph Nodes Matter in Breast Cancer Patients with Limited Nodal Burden? A Descriptive Cohort Study.}},
author = {Geok Hoon Lim and Me Me Win Htein and Fuh Yong Wong and Maria Ileana Syliangco and Seyed Ehsan Saffari},
journal = {Medical sciences (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/medsci14060689},
url = {https://europepmc.org/article/MED/42930608},
note = {CC BY},
}
RIS
TY - JOUR
TI - Does the Number of Harvested Sentinel Lymph Nodes Matter in Breast Cancer Patients with Limited Nodal Burden? A Descriptive Cohort Study.
AU - Geok Hoon Lim
AU - Me Me Win Htein
AU - Fuh Yong Wong
AU - Maria Ileana Syliangco
AU - Seyed Ehsan Saffari
PY - 2026
DA - 2026/10/20
JO - Medical sciences (Basel, Switzerland)
DO - 10.3390/medsci14060689
UR - https://europepmc.org/article/MED/42930608
AB - Background/Objectives: In breast cancer patients with limited nodal burden, sentinel lymph node biopsy (SLNB) alone, without axillary lymph node dissection (ALND), has shown non-inferior survival. However, it remains unclear how many SLNs should be harvested. We aimed to determine if the number of harvested SLNs and the use of a single agent for SLNB localisation affect the detection of residual metastatic nodes. We also described the oncological outcome of SLNB alone as an exploratory clinical outcome. Methods: From 1 January 2020 to 31 January 2026, T1-2 patients and 1-2 metastatic SLNs who underwent SLNB only or with completion ALND were analysed. The number of SLNs harvested and the use of single or dual agents for localisation of SLNs were analysed in the ALND group to determine if it affected the detection of residual metastatic nodes. Data on oncological outcomes were reported. Results: A total of 152 patients were enrolled, of which 63 and 89 underwent SLNB alone and ALND respectively. The ALND group had more patients with mastectomy (p = 0.0044), macrometastasis (p = 0.0001) and no radiation to the axilla (p = 0.0001). Median number of harvested SLNs was 3 (range: 1-8) and 2 (range: 1-9) in the SLNB and ALND groups respectively. In the ALND group, a mean residual 2.4 metastatic nodes (range: 1-9) was seen in 24.7%. Multivariable logistic regression showed that a higher SLN yield was not associated with less residual disease (adjusted OR 0.71 per additional SLN, 95% CI [0.46, 1.12]). Conversely, the number of metastatic SLNs was statistically associated with residual nodal disease OR 3.6 95% CI [1.19, 10.86]. Single-agent SLNB localisation (mainly patent blue dye) was used in 22% and 19.3% of SLNB and ALND group respectively. Though dual-agent localisation had more patients with ≥2 SLNs (p = 0.0181), it was not statistically associated with residual nodal metastatic disease which occurred in 7/17 (41.2%) single-agent versus 15/71 (21.1%) dual-agent cases (p = 0.1184; OR 2.58, 95% CI [0.71, 9.09]). No recurrences were observed on a median follow-up of 37 (range: 3-75) months. Conclusions: The number of harvested SLNs and the use of patent blue dye as a single-agent localisation were not statistically associated with residual nodal disease in patients with limited nodal burden. Instead, metastatic SLN burden was statistically significant for residual nodal disease. However, our findings were limited by small sample size and should be considered as exploratory in nature with validation needed in larger studies with longer follow-up.
SN - 2076-3271
ER -